前立腺がんの世界市場：洞察、競合情勢、市場予測：2030年

世界の前立腺がんの市場規模は、2023年に82億5,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に4.96％のCAGRで拡大し、2030年には110億1,100万米ドルに達すると予測されています。前立腺がん診断薬および治療薬に対する需要は、主に世界中で前立腺がんの罹患率が増加していること、前立腺がんのリスク因子が増加していること、前立腺がん診断薬における技術進歩が拡大していること、政府および非政府の啓発活動、その他の活動の増加などが、2024年～2030年の予測期間における前立腺がん市場全体の成長にさらに寄与しています。

前立腺がんは、男性に2番目に多く発生するがんであり、4番目に多いがんです。Global Cancer Observatory（2023年）が発表したデータによると、2020年には世界で約141万人の前立腺がん新規症例が報告され、2040年にはこの数は224万人に達する見込みです。同出典によると、2020年に前立腺がんの発生率が最も高かったのは欧州（473,344人）で、次いでアジア（371,225人）、北米（239,574人）、ラテンアメリカおよびカリブ海諸国（214,522人）、アフリカ（93,173人）でした。

Prostate Cancer UK（2023年）によると、英国では毎年平均52,000人の男性が前立腺がんと診断され、毎日143人が前立腺がんと診断されています。この情報源はさらに、イングランドでは毎年47,000人近くの男性が前立腺がんと診断されると述べています。

当レポートでは、世界の前立腺がん市場について調査し、市場の概要とともに、製品タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 前立腺がん市場レポートのイントロダクション

第2章 前立腺がん市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 前立腺がん市場の主な要因分析

• 前立腺がん市場の促進要因
• 前立腺がん市場の抑制要因と課題
• 前立腺がん市場の機会

第5章 前立腺がん市場におけるポーターのファイブフォース分析

第6章 前立腺がん市場に対するCOVID-19の影響分析

第7章 前立腺がん市場の概要

• 製品タイプ別
• エンドユーザー別
• 地域別

第8章 前立腺がん市場の企業と製品プロファイル

• Proteomedix
• A3P Biomedical
• GE HealthCare
• Soteria Medical BV
• Bio-Techne
• F. Hoffmann-La Roche Ltd.
• Indica Labs Inc.
• OPKO HEALTH, INC.
• miR Scientific, LLC
• MINOMIC®
• Novartis AG
• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Cipla
• Bayer AG
• AstraZeneca
• Zydus Cadila
• Pfizer Inc.
• Avenda Health
• The Sanpower Group

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Prostate Cancer Market in Global (2021-2030)
• Table 4: Prostate Cancer Market in Global by Product Type (2021-2030)
• Table 5: Prostate Cancer Market in Global by End-User (2021-2030)
• Table 6: Prostate Cancer Market in Global by Geography (2021-2030)
• Table 7: Prostate Cancer Market in North America (2021-2030)
• Table 8: Prostate Cancer Market in North America by Country (2021-2030)
• Table 9: Prostate Cancer Market in the US (2021-2030)
• Table 10: Prostate Cancer Market in Canada (2021-2030)
• Table 11: Prostate Cancer Market in Mexico (2021-2030)
• Table 12: Prostate Cancer Market in Europe (2021-2030)
• Table 15: Prostate Cancer Market in Europe by Country (2021-2030)
• Table 16: Prostate Cancer Market in France (2021-2030)
• Table 17: Prostate Cancer Market in Germany (2021-2030)
• Table 18: Prostate Cancer Market in the United Kingdom (2021-2030)
• Table 19: Prostate Cancer Market in Italy (2021-2030)
• Table 20: Prostate Cancer Market in Spain (2021-2030)
• Table 21: Prostate Cancer Market in the Rest of Europe (2021-2030)
• Table 22: Prostate Cancer Market in Asia-Pacific (2021-2030)
• Table 23: Prostate Cancer Market in Asia-Pacific by Country (2021-2030)
• Table 24: Prostate Cancer Market in China (2021-2030)
• Table 25: Prostate Cancer Market in Japan (2021-2030)
• Table 26: Prostate Cancer Market in India (2021-2030)
• Table 27: Prostate Cancer Market in Australia (2021-2030)
• Table 28: Prostate Cancer Market in South Korea (2021-2030)
• Table 29: Prostate Cancer Market in Rest of Asia-Pacific (2021-2030)
• Table 30: Prostate Cancer Market in the Rest of the World (2021-2030)
• Table 31: Prostate Cancer Market in RoW by Region (2021-2030)
• Table 33: Prostate Cancer Market in the Middle East (2021-2030)
• Table 34: Prostate Cancer Market in Africa (2021-2030)
• Table 35: Prostate Cancer Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Prostate Cancer Market in Global (2021-2030)
• Figure 4: Prostate Cancer Market in Global by Product Type (2021-2030)
• Figure 5: Prostate Cancer Market in Global by End-User (2021-2030)
• Figure 6: Prostate Cancer Market in Global by Geography (2021-2030)
• Figure 7: Prostate Cancer Market in North America (2021-2030)
• Figure 8: Prostate Cancer Market in North America by Country (2021-2030)
• Figure 9: Prostate Cancer Market in the US (2021-2030)
• Figure 10: Prostate Cancer Market in Canada (2021-2030)
• Figure 11: Prostate Cancer Market in Mexico (2021-2030)
• Figure 12: Prostate Cancer Market in Europe (2021-2030)
• Figure 15: Prostate Cancer Market in Europe by Country (2021-2030)
• Figure 16: Prostate Cancer Market in France (2021-2030)
• Figure 17: Prostate Cancer Market in Germany (2021-2030)
• Figure 18: Prostate Cancer Market in the United Kingdom (2021-2030)
• Figure 19: Prostate Cancer Market in Italy (2021-2030)
• Figure 20: Prostate Cancer Market in Spain (2021-2030)
• Figure 21: Prostate Cancer Market in the Rest of Europe (2021-2030)
• Figure 22: Prostate Cancer Market in Asia-Pacific (2021-2030)
• Figure 23: Prostate Cancer Market in Asia-Pacific by Country (2021-2030)
• Figure 24: Prostate Cancer Market in China (2021-2030)
• Figure 25: Prostate Cancer Market in Japan (2021-2030)
• Figure 26: Prostate Cancer Market in India (2021-2030)
• Figure 27: Prostate Cancer Market in Australia (2021-2030)
• Figure 28: Prostate Cancer Market in South Korea (2021-2030)
• Figure 29: Prostate Cancer Market in Rest of Asia-Pacific (2021-2030)
• Figure 30: Prostate Cancer Market in the Rest of the World (2021-2030)
• Figure 31: Prostate Cancer Market in RoW by Region (2021-2030)
• Figure 32: Prostate Cancer Market in the Middle East (2021-2030)
• Figure 33: Prostate Cancer Market in Africa (2021-2030)
• Figure 34: Prostate Cancer Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Prostate Cancer Market By Product Type (Diagnosis [Blood Test, Imaging Test, Biopsy, And Others] And Treatment [Therapeutics {Chemotherapy, Hormonal Therapy, And Others}, Radiation Therapy, Surgery, And Others]), End-User (Hospitals, Speciality Clinics, Diagnostic Centers, And Others), And By Geography Is Expected To Grow At A Steady Cagr Forecast till 2030 Owing To The Rising Incidence For Prostate Cancer And Growing Awareness On Prostate Cancer Among Men

The global prostate cancer market was valued at USD 8,250 million in 2023, growing at a CAGR of 4.96% during the forecast period from 2024 to 2030 to reach USD 11,011 million by 2030. The demand for prostate cancer diagnostics and therapeutics is primarily being boosted by the increasing incidence of prostate cancer across the world, the rising number of risk factors for prostate cancer, growing technological advancements in prostate cancer diagnostics, government, and non-government awareness initiatives, and increasing product development activities among others are further contributing in the overall growth of the prostate cancer market during the forecast period from 2024-2030.

Prostate Cancer Market Dynamics:

Prostate cancer is the second most commonly occurring cancer in men and the fourth most common cancer. The data published by Global Cancer Observatory (2023) says that globally around 1.41 million new cases of prostate cancer were reported in 2020 and by 2040 this number is expected to reach 2.24 million. As per the same source, Europe (473,344) recorded the highest incidence of prostate cancer in 2020, followed by Asia (371,225), North America (239,574), Latin America and the Caribbean (214,522), and Africa (93,173).

As per Prostate Cancer UK (2023), every year on average 52,000 men are diagnosed with prostate cancer in the United Kingdom and this makes 143 men every day. The source further stated that nearly 47,000 men are diagnosed with prostate cancer every year in England.

The American Cancer Society (2023) highlights the relationship between old age and prostate cancer and says that the risk for prostate cancer rises rapidly after age 50 and about 6 in 10 cases of prostate cancer are reported in men older than 65. Thereby, the increasing population of aged men susceptible to prostate cancer is going to increase the demand for prostate cancer diagnostics and therapeutics. For instance, according to WHO 2022, it has been expected that, globally by 2030, out of 6 at least 1 person will have his/her age 60 years or above. As per the same source, by 2050, the number of people aged 60 years or above will reach around 2.1 billion.

The increasing number of research and development activities for prostate cancer is expected to escalate the market for the same. For instance, in March 2023 Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence (BCR).

However, risks associated with prostate cancer diagnostics and therapeutics and the stigmatization of prostate cancer may restrict the growth of the overall prostate cancer market.

The Prostate Cancer market was largely impacted during the COVID-19 pandemic owing to lockdown impositions as a measure to prevent the spread of COVID-19 infection which led to the closure of oncology departments in hospitals, clinics, and other medical facilities leading to disruption in diagnosis and treatment services for prostate cancer. The manufacturing, processing, supply, distribution, import, export, and other related activities of the prostate cancer market were severely hampered, thereby negatively impacting the growth of the prostate cancer market. Nevertheless, the prostate cancer market is in a recovery phase owing to the introduction of vaccines against COVID-19 and the resumption of activities across all sectors including healthcare and pharmaceutical, thereby providing ample opportunities for the prostate cancer market to grow at significant revenue during the forecast period.

Prostate Cancer Market Segment Analysis:

Prostate Cancer market by Product Type (Diagnosis [Blood Test, Imaging Test, Biopsy, and Others] and Treatment [Therapeutics {Chemotherapy, Hormonal Therapy, and Others}, Radiation Therapy, Surgery, and Others]), End-User (Hospitals, Speciality Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the Prostate Cancer market, the blood test category under-diagnosis is expected to amass a significant revenue share in the year 2023. The prostate-specific antigen (PSA) blood test is largely used for detecting the presence of prostate cancer. It is the first test authorized by healthcare professionals for men who are presenting symptoms that might be related to prostate cancer. The test is also suitable for use in individuals with no symptoms.

The rise in the level of PSA usually 4 ng/mL or higher particularly in men aged 50 or above indicates the presence of prostate cancer. As per the American Cancer Society, men with a PSA level ranging between 4 and 10 which is often referred to as borderline range have about a 1 in 4 chance of having prostate cancer, and if the PSA level is more than 10, the chance of having prostate cancer is over 50%.

PSA blood test can help in the detection of early signs of cancer and allows for timely treatment and a greater chance of survival. Many physicians thereby recommend annual prostate-specific antigen tests (PSA) for males aged 50 years or above.

Sangia total prostate-specific antigen (PSA) by Opko Health Inc. quantitatively measures total PSA from a fingerstick of whole blood collected by a healthcare professional and is used in conjunction with a digital rectal exam as an aid in the detection of prostate cancer in men aged 50 years and older.

The test can also be used in patients who have undergone tumor removal surgery to check if cancer has recurred or not. It can also be used to determine whether the cancer is growing or shrinking post-treatment with hormones or radiation.

Therefore, considering the advantages associated with a blood test and their growing usage, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global prostate cancer market during the forecast period.

North America is expected to dominate the overall Prostate Cancer Market:

Among all the regions, North America is estimated to account for the largest share of the Prostate Cancer market in the year 2023. Owing to the significance of key growth factors such as the increasing patient population suffering from prostate cancer, sophisticated healthcare infrastructure, government programs, presence of key players, and fast regulatory approval for new products, among others, the market for prostate cancer is expected to register a significant growth in the region.

According to Global Cancer Observatory 2020, it was estimated that there were about 454 thousand cases of prostate cancer diagnosed in the US in 2020. The source further stated that by 2040 around 696 thousand new cases are going to be reported in the United States. As per Centers for Disease Control and Prevention 2023, nearly 224,733 new cases of prostate cancer were reported in 2019 making it the second most common cancer among men in the United States.

The role of government and non-government organizations in creating awareness regarding the disease in the region is going to positively impact the market for prostate cancer. ZERO Prostate Cancer is the leading national nonprofit organization based in the United States whose mission is to end prostate cancer and help all who are impacted. It offers support to prostate cancer patients by educating them about the disease and by providing diagnostic and treatment facilities to the individuals. It also provides financial assistance to patients who cannot afford prostate cancer treatment.

The increasing number of product development activities in the region is going to accelerate the growth of the prostate cancer market. For example, in November 2022, a Leuprolide acetate injection by Amneal Pharmaceuticals was approved by the US Food and Drug Administration for patients with advanced prostate cancer.

Hence, the above-mentioned factors are going to increase the growth of the prostate cancer market in the region.

Prostate Cancer Market Key Players:

Some of the key market players operating in the Prostate Cancer market include Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, and others.

Recent Developmental Activities in the Prostate Cancer Market:

In February 2023, Orion Corporation received Japan's Ministry of Health, Labor and Welfare (MHLW) approval for the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer.

In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved PluvictoTM for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body.

In December 2021, OPKO Health, Inc., received the US FDA approval for 4Kscore Test.

Key Takeaways from the Prostate Cancer Market Report Study

Market size analysis for current prostate cancer market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the prostate cancer market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global prostate cancer market.

Various opportunities available for the other competitor in the prostate cancer market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current prostate cancer market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for prostate cancer market growth in the coming future?

Target Audience who can be benefited from this Prostate Cancer Market Report Study

Prostate Cancer products providers

Research organizations and consulting companies

Prostate Cancer- related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Prostate Cancer

Various End-users who want to know more about the Prostate Cancer market and the latest innovations and developments in the Prostate Cancer market.

Frequently Asked Questions for the Prostate Cancer Market:

1. What is prostate cancer?

Prostate cancer is a cancer of the prostate gland which is a part of the male reproductive system.

2. What is the market for global prostate cancer?

The global prostate cancer market was valued at USD 8,250 million in 2023, growing at a CAGR of 4.96% during the forecast period from 2024 to 2030 to reach USD 11,011 million by 2030.

3. What are the drivers for the global prostate cancer market?

The growth of the prostate cancer market is primarily being boosted by the increasing number of cases of prostate cancer, the rising number of risks factors associated with prostate cancer, growing awareness regarding prostate cancer among men, increasing research and development activities, increasing technological advancements such as the incorporation of artificial intelligence (AI) in prostate cancer diagnosis, and government and non-government initiatives for prostate cancer among others are contributing to the overall growth of the prostate cancer market during the forecast period from 2024-2030.

4. Who are the key players operating in the global prostate cancer market?

Some of the key market players operating in the prostate cancer market include Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, and others.

5. Which region has the highest share in the prostate cancer market?

North America is expected to dominate the overall prostate cancer market during the forecast period from 2024-2030. Factors such as the increasing men population suffering from prostate cancer, the growing burden of aged men, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new products, and high awareness are driving the growth of the prostate cancer market in the region.

Table of Contents

1.Prostate Cancer Market Report Introduction

2. Prostate Cancer Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Prostate Cancer Market Key Factors Analysis

• 4.1. Prostate Cancer Market Drivers
  • 4.1.1. Rising incidence of prostate cancer and its risk factors
  • 4.1.2. Initiatives by government and non-government organizations to create awareness for prostate cancer diagnosis
  • 4.1.3. Growing application of artificial intelligence (AI) in prostate cancer diagnosis and treatment
• 4.2. Prostate Cancer Market Restraints and Challenges
  • 4.2.1. Risks associated with prostate cancer diagnostics and therapeutics
  • 4.2.2. Stigmatization of prostate cancer
• 4.3. Prostate Cancer Market Opportunities
  • 4.3.1. Personalized medicine for prostate cancer
  • 4.3.2. Advances in potential molecular markers of prostate cancer

5. Prostate Cancer Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on the Prostate Cancer Market

7. Prostate Cancer Market Layout

• 7.1. By Product Type
  • 7.1.1. Diagnosis
    • 7.1.1.1. Blood Test
    • 7.1.1.2. Imaging Test
    • 7.1.1.3. Biopsy
    • 7.1.1.4. Others
  • 7.1.2. Treatment
    • 7.1.2.1. Therapeutics
    • 7.1.2.1.1. Chemotherapy
    • 7.1.2.1.2. Hormonal Therapy
    • 7.1.2.1.3. Others
    • 7.1.2.2. Radiation Therapy
    • 7.1.2.3. Surgery
    • 7.1.2.4. Others
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Specialty Clinics
  • 7.2.3. Diagnostic Centers
  • 7.2.4. Others
• 7.3. By Geography
  • 7.3.1. North America Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.1.1. United States Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Prostate Cancer Market Size in USD million (2021-2030)
  • 7.3.2. Europe Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.1. France Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Prostate Cancer Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.1. China Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.3. India Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Prostate Cancer Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW) Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.4.1. Middle East Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Prostate Cancer Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Prostate Cancer Market Size in USD million (2021-2030)

8. Prostate Cancer Market Company and Product Profiles

• 8.1. Proteomedix
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. A3P Biomedical
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GE HealthCare
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Soteria Medical BV
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Bio-Techne
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. F. Hoffmann-La Roche Ltd.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Indica Labs Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. OPKO HEALTH, INC.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. miR Scientific, LLC
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. MINOMIC®
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Novartis AG
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Johnson & Johnson Services, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Astellas Pharma Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Cipla
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Bayer AG
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. AstraZeneca
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Zydus Cadila
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Pfizer Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Avenda Health
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. The Sanpower Group
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us